People In Health Care
Dr Marina Berbic
Genetic Pathologist and Deputy Director of Genetics
Douglass Hanly Moir Pathology
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
Australian Health Journal spoke to Dr Berbic about her career and being a genetic pathologist. She started as a junior doctor in obstetrics and gynaecology after completing a medical degree, though never thought about specialising in pathology. The more she learned about genetic pathology, the more intrigued she became, realising that this specialty aligned with both her strengths and interests.
Dr Berbic has always been interested in science, technology, and innovation. She first studied for a Bachelor of Medical Science degree, followed by a Master’s in Reproductive Health and Human Genetics and then a PhD in Reproductive Medicine. Dr Berbic has long-standing academic interests, both from a research and teaching perspective. She continues to be involved in medical education at the University of New South Wales in her role as an Adjunct Senior Lecturer.
After completing her specialist training and attaining fellowship of the Royal College of Pathologists of Australasia, she commenced her role as a genetic pathologist at Douglass Hanly Moir and later became the Deputy Director of Genetics department. Her role involves providing clinical governance and medical leadership that governs all aspects of medical testing in genetics.
In this interview, Dr Berbic talks about the exciting area of genetic pathology impacting multiple areas of medicine including paediatrics, obstetrics and gynaecology, cardiology, neurology, oncology, and other fields.
The results of genetic testing have a potential impact on the patient’s diagnosis, the decisions that couples may take when they’re making reproductive decisions, and also have predictive implications. The testing results may influence therapy, selection, or patient management and may have far ranging impact on the individual as well as their family.
You Might also like
-
Lens on patient care & allied health workforce across settings
The CEO of Allied Health Professions Australia (AHPA), Bronwyn Morris-Donovan spoke with Australian Health Journal about the following:
The structure and priorities for AHPA
The setting and disciplines in Allied Health
Allied Health representation in the Strengthening Medicare Task Force
Importance of a data strategy and interoperability in delivery of allied health services
Key allied health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
State of Private Hospitals sector in Australia
During Mr Roff’s working career at APHA he has represented the private hospitals sector to nine different Federal Health Ministers and eight Prime Ministers. He believes the government should take steps to regulate the health insurance industry to protect consumers and ensure that Australians have access to affordable and comprehensive healthcare services.
-
Growing impact of blood cancer on women
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).